Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Orphanet Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
Symbol TRPC6 contributors: mct/shn/pgu - updated : 22-05-2024
HGNC name transient receptor potential cation channel, subfamily C, member 6
HGNC id 12338
corresponding disease(s) FSGS2
Other morbid association(s)
TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
tumoral     --over  
upregulated in gastric cancer epithelial cells
constitutional       gain of function
is involved in Ca(2+) signaling and actin reorganization in podocytes after oxygen glucose deprivation (OGD)
  • to idiopathic membranous glomerulopathy (iMN)
  • Variant & Polymorphism SNP
  • a SNP in the promoter region and a missense variant in exon 4 may be putative causal variants for infantile hypertrophic pyloric stenosis
  • 254C->G SNP may predispose individuals to an increased risk of idiopathic pulmonary arterial hypertension
  • genetic variants in TRPC6 might affect susceptibility to development or progression of iMN
  • Candidate gene
    Therapy target
    newly-identified ROS/TRPC6 pathway will pave the way to new, promising therapeutic strategies to target kidney diseases such as diabetic nephropathy
    manipulation of TRPC6 function may thus offer a therapeutic strategy for the control of pulmonary hemodynamics and gas exchange
    activation by hyperforin may represent a new innovative therapeutic strategy in skin disorders characterized by altered keratinocyte differentiation
    key mediator of tumor growth of glioblastoma multiforme (GBM) and may be a promising therapeutic target in the treatment of GBM
    cardiovascularaquiredheart failure
    . pharmacologic inhibitors of TRPC channels might be a strategy for attenuating local Ca2+ signals involved in pathologic cardiac hypertrophy or failure
    TRPC6 channel is a good target for developing novel treatment for pulmonary arterial hypertension (PAH), and BI-749327, a selective TRPC6 blocker, is potentially a novel and effective drug for treating PAH
    TRPC6 might aggravate SARS COV-2 induced inflammation and could be a target for inhibiting drugs
  • in TRPC6-/- mice, a higher contractility in isolated tracheal and aortic rings was observed following application of the agonists methacholine and phenylephrine, respectively, as well as a reduced agonist-induced expiration rate (